{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:47:19Z","timestamp":1790668039433,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40266-018-00636-7","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T04:36:40Z","timestamp":1548391000000},"page":"309-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Pharmacological Management of Dementia with Lewy Bodies"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-6634","authenticated-orcid":false,"given":"Linda A.","family":"Hershey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Coleman-Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"636_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1212\/WNL.0000000000000894","volume":"83","author":"AR Mason","year":"2014","unstructured":"Mason AR, Ziemann A, Finkbeiner S. Targeting the low-hanging fruit of neurodegeneration. Neurology. 2014;83:1470\u20133.","journal-title":"Neurology"},{"issue":"11","key":"636_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1001\/jamaneurol.2013.3579","volume":"70","author":"R Savica","year":"2013","unstructured":"Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396\u2013402.","journal-title":"JAMA Neurol"},{"key":"636_CR3","first-page":"57","volume":"80","author":"E Farina","year":"2009","unstructured":"Farina E, Baglio F, Caffarra P, Magnani G, Scarpini E, Appollonio I, et al. Frequency and clinical features of Lewy body dementia in Italian memory clinics. Acta Biomed. 2009;80:57\u201364.","journal-title":"Acta Biomed"},{"key":"636_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/brain\/awp280","volume":"133","author":"J Molano","year":"2010","unstructured":"Molano J, Boeve B, Ferman T, Smith G, Parisi J, Dickson D, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. 2010;133:540\u201356.","journal-title":"Brain"},{"key":"636_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson D, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"issue":"9","key":"636_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jamainternmed.2015.2152","volume":"175","author":"KK Tsoi","year":"2015","unstructured":"Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450\u20138.","journal-title":"JAMA Intern Med"},{"key":"636_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011145.pub2","author":"ST Creavin","year":"2016","unstructured":"Creavin ST, Wisniewski S, Noel-Storr AH, Trevelyan CM, Hampton T, Rayment D, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016. \n                              https:\/\/doi.org\/10.1002\/14651858.cd011145.pub2\n                              \n                           .","journal-title":"Cochrane Database Syst Rev"},{"key":"636_CR8","doi-asserted-by":"publisher","first-page":"6903270020","DOI":"10.5014\/ajot.2014.015198","volume":"69","author":"C Ciro","year":"2015","unstructured":"Ciro C, Anderson MP, Hershey LA, Prodan CI, Holm MB. Instrumental activities of daily living performance and role satisfaction in people with and without mild cognitive impairment: a pilot project. Am J Occup Ther. 2015;69:6903270020. \n                              https:\/\/doi.org\/10.5014\/ajot.2015.015198\n                              \n                           .","journal-title":"Am J Occup Ther"},{"issue":"3","key":"636_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1159\/000441184","volume":"5","author":"A Cagnin","year":"2015","unstructured":"Cagnin A, Busse C, Gardini S, Jelnic N, Guzzo C, Gnoato F, et al. Clinical and cognitive phenotype of mild cognitive impairment evolving to dementia with Lewy bodies. Dement Geriatr Cogn Disord Extra. 2015;5(3):442\u20139.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"4","key":"636_CR10","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1176\/appi.neuropsych.11090212","volume":"24","author":"PR Teng","year":"2012","unstructured":"Teng PR, Yeh CH, Lin CY, Lai TJ. Olanzapine-induced neuroleptic malignant syndrome in a patient with probable dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 2012;24(4):E1\u20132.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"636_CR11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1212\/WNL.0000000000003371","volume":"87","author":"K Kantarci","year":"2016","unstructured":"Kantarci K, Lesnick T, Ferman TJ, Przybelski SA, Boeve BF, Smith GE, et al. Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology. 2016;87:2317\u201323.","journal-title":"Neurology"},{"key":"636_CR12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","volume":"60","author":"AR Merdes","year":"2003","unstructured":"Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60:1586\u201390.","journal-title":"Neurology"},{"issue":"5","key":"636_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1365-2990.2003.00453.x","volume":"29","author":"Y Tsuboi","year":"2003","unstructured":"Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson D. Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol. 2003;29(5):503\u201310.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"636_CR14","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Avanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community dwelling older persons. Neurology. 2007;69:2197\u2013204.","journal-title":"Neurology"},{"issue":"10","key":"636_CR15","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00415-014-7439-z","volume":"261","author":"MJ Grothe","year":"2014","unstructured":"Grothe MJ, Schuster C, Bauer F, Heinsen H, Prudlo J, Teipel SJ. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer\u2019s disease dementia. J Neurol. 2014;261(10):1939\u201348.","journal-title":"J Neurol"},{"issue":"5","key":"636_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/WNL.56.5.643","volume":"56","author":"K Lobotesis","year":"2001","unstructured":"Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56(5):643\u20139.","journal-title":"Neurology"},{"key":"636_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.0000000000000734","volume":"83","author":"J Graff-Radford","year":"2014","unstructured":"Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology. 2014;83:801\u20139.","journal-title":"Neurology"},{"key":"636_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ana.410420114","volume":"42","author":"S Minoshima","year":"1997","unstructured":"Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer\u2019s disease. Ann Neurol. 1997;42:85\u201394.","journal-title":"Ann Neurol"},{"issue":"12","key":"636_CR19","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2967\/jnumed.114.143347","volume":"55","author":"JT O\u2019Brien","year":"2014","unstructured":"O\u2019Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med. 2014;55(12):1959\u201365.","journal-title":"J Nucl Med"},{"issue":"7","key":"636_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","volume":"30","author":"M Petrou","year":"2015","unstructured":"Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Muller ML, et al. Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review. Mov Disord. 2015;30(7):928\u201335.","journal-title":"Mov Disord"},{"issue":"2","key":"636_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00019442-200403000-00009","volume":"12","author":"DW Tsuang","year":"2004","unstructured":"Tsuang DW, DiGiacomo L, Bird TD. Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry. 2004;12(2):179\u201388.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"636_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archneurol.2010.319","volume":"68","author":"A Nervi","year":"2011","unstructured":"Nervi A, Reitz C, Tang MX, Santana V, Piriz A, Reyes D, et al. Familial aggregation of dementia with Lewy bodies. Arch Neurol. 2011;68(1):90\u20133.","journal-title":"Arch Neurol"},{"issue":"1","key":"636_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","volume":"17","author":"R Guerreiro","year":"2018","unstructured":"Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2018;17(1):64\u201374.","journal-title":"Lancet Neurol"},{"issue":"11","key":"636_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000256715.13907.d3","volume":"68","author":"CF Lippa","year":"2007","unstructured":"Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812\u20139.","journal-title":"Neurology"},{"issue":"1","key":"636_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Steiber A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72(1):57\u201371.","journal-title":"Neuron"},{"key":"636_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","volume":"89","author":"V Donadio","year":"2017","unstructured":"Donadio V, Insensi A, Rizzo G, Capellari S, Pantieri R, Maserati MS, et al. A new potential biomarker for dementia with Lewy bodies: skin nerve alpha-synuclein deposits. Neurology. 2017;89:318\u201326.","journal-title":"Neurology"},{"key":"636_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ana.20819","volume":"59","author":"WR Galpern","year":"2006","unstructured":"Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol. 2006;59:449\u201358.","journal-title":"Ann Neurol"},{"issue":"1","key":"636_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16(1):55\u201365.","journal-title":"Lancet Neurol"},{"issue":"7","key":"636_CR29","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181\u201393.","journal-title":"Brain"},{"issue":"9247","key":"636_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, DelSer T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031\u20136.","journal-title":"Lancet"},{"issue":"6","key":"636_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000101512","volume":"23","author":"K Edwards","year":"2007","unstructured":"Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23(6):401\u20135.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"636_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd006504.pub2","author":"M Rolinski","year":"2012","unstructured":"Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2012. \n                              https:\/\/doi.org\/10.1002\/14651858.cd006504.pub2\n                              \n                           .","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"636_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori E, Ikeda M, Kosaka K, Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41\u201352.","journal-title":"Ann Neurol"},{"issue":"2","key":"636_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"HF Wang","year":"2015","unstructured":"Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"636_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.nbd.2010.10.013","volume":"41","author":"R Warre","year":"2011","unstructured":"Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, et al. Altered function of glutaminergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol Dis. 2011;41(3):591\u2013604.","journal-title":"Neurobiol Dis"},{"key":"636_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, Bastrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multi-centre trial. Lancet Neurol. 2009;8:613\u20138.","journal-title":"Lancet Neurol"},{"issue":"10","key":"636_CR37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonucelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"issue":"11","key":"636_CR38","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1517\/14656566.4.11.2027","volume":"4","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027\u201337.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"636_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12877-018-0740-4","volume":"18","author":"I Zahirovic","year":"2018","unstructured":"Zahirovic I, Torisson G, Wattmo C, Londos E. Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study on 40 nursing homes in Sweden. BMC Geriatr. 2018;18(1):50.","journal-title":"BMC Geriatr"},{"issue":"17","key":"636_CR40","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, Thal L, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356\u201363.","journal-title":"Neurology"},{"key":"636_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1212\/CPJ.0000000000000342","volume":"7","author":"T Hawkins","year":"2017","unstructured":"Hawkins T, Berman B. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017;7:157\u201362.","journal-title":"Neurol Clin Pract"},{"issue":"15","key":"636_CR42","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/mds.22322","volume":"23","author":"JG Goldman","year":"2008","unstructured":"Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248\u201350.","journal-title":"Mov Disord"},{"key":"636_CR43","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized, double-blind phase 2 study. Neurology. 2018;90:e664\u201372.","journal-title":"Neurology"},{"issue":"8","key":"636_CR44","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1212\/WNL.54.8.1616","volume":"54","author":"MP Walker","year":"2000","unstructured":"Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O\u2019Brien JT, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer\u2019s disease, and vascular dementia. Neurology. 2000;54(8):1616\u201325.","journal-title":"Neurology"},{"key":"636_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ageing\/afq140","volume":"40","author":"A Clegg","year":"2011","unstructured":"Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40:23\u20139.","journal-title":"Age Ageing"},{"key":"636_CR46","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/CIA.S68557","volume":"9","author":"MG Figueiro","year":"2014","unstructured":"Figueiro MG, Plitnick BA, Lok A, Jones GE, Higgins P, Hornick TR, et al. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer\u2019s disease and related dementia living in long-term care facilities. Clin Interv Aging. 2014;9:1527\u201337.","journal-title":"Clin Interv Aging"},{"key":"636_CR47","doi-asserted-by":"publisher","first-page":"e000380","DOI":"10.1136\/bmjopen-2011-000380","volume":"2","author":"Z Walker","year":"2012","unstructured":"Walker Z, McKeith I, Rodda J, Qassem T, Tatsch K, Booij J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer\u2019s disease: a cohort study. BMJ Open. 2012;2:e000380.","journal-title":"BMJ Open"},{"issue":"15","key":"636_CR48","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med. 2006;355(15):1525\u201338.","journal-title":"N Engl J Med"},{"issue":"2","key":"636_CR49","first-page":"1007","volume":"1","author":"LA Hershey","year":"2014","unstructured":"Hershey LA, Aggarwal R, Jindal P, Baranskaya I. Managing agitation in Alzheimer disease and related disorders. JSM Alzheimers Dis Relat Dement. 2014;1(2):1007.","journal-title":"JSM Alzheimers Dis Relat Dement"},{"key":"636_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0897190011424802","volume":"25","author":"CR Dolder","year":"2012","unstructured":"Dolder CR, Nealy KL, McKinsey J. Valproic acid in dementia: does an optimal dose exist? J Pharm Pract. 2012;25:142\u201350.","journal-title":"J Pharm Pract"},{"key":"636_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003945.pub3","author":"E Lonergan","year":"2009","unstructured":"Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009. \n                              https:\/\/doi.org\/10.1002\/14651858.CD003945.pub3\n                              \n                           .","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"636_CR52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.psym.2015.09.008","volume":"56","author":"Y Sher","year":"2015","unstructured":"Sher Y, Miller Cramer AC, Ament A, Lolak S, Maldonado JR. Valproic acid for treatment of hyperactive or mixed delirium: rationale and literature review. Psychosomatics. 2015;56(6):615\u201325.","journal-title":"Psychosomatics"},{"key":"636_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcrc.2016.09.006","volume":"37","author":"DJ Gagnon","year":"2017","unstructured":"Gagnon DJ, Fontaine GV, Smith KE, Riker RR, Miller RR 3rd, Lerwick PA, et al. Valproate for agitation in critically ill patients: a retrospective study. J Crit Care. 2017;37:119\u201325.","journal-title":"J Crit Care"},{"issue":"2","key":"636_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/sleep\/9.2.293","volume":"9","author":"CH Schenck","year":"1986","unstructured":"Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293\u2013308.","journal-title":"Sleep"},{"issue":"15","key":"636_CR55","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1212\/01.wnl.0000340980.19702.6e","volume":"72","author":"RB Postuma","year":"2009","unstructured":"Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296\u2013300.","journal-title":"Neurology"},{"key":"636_CR56","doi-asserted-by":"publisher","first-page":"9421098","DOI":"10.1155\/2018\/9421098","volume":"2018","author":"PC Chan","year":"2018","unstructured":"Chan PC, Lee HH, Hong CT, Hu CJ, Wu D. REM sleep behavior disorder (RBD) in dementia with Lewy bodies (DLB). Behav Neurol. 2018;2018:9421098. \n                              https:\/\/doi.org\/10.1155\/2018\/9421098\n                              \n                           .","journal-title":"Behav Neurol"},{"key":"636_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1017\/S1355617702870047","volume":"8","author":"TJ Ferman","year":"2002","unstructured":"Ferman TJ, Boeve BF, Smith GE, Silber MH, Lucas JA, Graff-Radford NR, et al. Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. J Int Neuropsychol Soc. 2002;8:907\u201314.","journal-title":"J Int Neuropsychol Soc"},{"key":"636_CR58","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1212\/WNL.0b013e31822c9148","volume":"77","author":"TJ Ferman","year":"2011","unstructured":"Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic accuracy of dementia with Lewy bodies. Neurology. 2011;77:875\u201382.","journal-title":"Neurology"},{"issue":"1","key":"636_CR59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5664\/jcsm.27717","volume":"6","author":"RN Aurora","year":"2010","unstructured":"Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85\u201395.","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"636_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sleep.2014.09.011","volume":"16","author":"IR McGrane","year":"2015","unstructured":"McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19\u201326.","journal-title":"Sleep Med"},{"issue":"4","key":"636_CR61","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","volume":"4","author":"BF Boeve","year":"2003","unstructured":"Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281\u20134.","journal-title":"Sleep Med"},{"issue":"1","key":"636_CR62","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/jpet.109.160994","volume":"332","author":"HA Al-Shamma","year":"2010","unstructured":"Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010;332(1):281\u201390.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"636_CR63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11910-017-0778-2","volume":"17","author":"L Velayudhan","year":"2017","unstructured":"Velayudhan L, Ffytche D, Ballard C, Aarsland D. New therapeutic strategies for Lewy body dementias. Curr Neurol Neurosci Rep. 2017;17(9):68.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"636_CR64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","volume":"11","author":"X Colodny","year":"2011","unstructured":"Colodny X, Vela JM, Ramirez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011;11(1):94\u2013100.","journal-title":"Curr Opin Pharmacol"},{"issue":"15","key":"636_CR65","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1080\/14656566.2018.1519548","volume":"19","author":"G Palermo","year":"2018","unstructured":"Palermo G, Ceravolo R, Bonuccelli U. Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opin Pharmacother. 2018;19(15):1643\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"636_CR66","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep. 2018;8(1):16165.","journal-title":"Sci Rep"},{"issue":"Pt5","key":"636_CR67","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, et al. Ambroxol improves lysosomal biochemistry in glucocerebrocidase mutation-linked Parkinson disease cells. Brain. 2014;137(Pt5):1481\u201395.","journal-title":"Brain"},{"issue":"1","key":"636_CR68","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.1038\/s41598-017-11664-5","volume":"7","author":"M Hollerhage","year":"2017","unstructured":"Hollerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, et al. Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep. 2017;7(1):11469. \n                              https:\/\/doi.org\/10.1038\/s41598-017-11664-5\n                              \n                           .","journal-title":"Sci Rep"},{"issue":"2","key":"636_CR69","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mds.26481","volume":"31","author":"AL Bergstrom","year":"2016","unstructured":"Bergstrom AL, Kallunki P, Fog K. Development of passive immunotherapies for synucleinopathies. Mov Disord. 2016;31(2):203\u201313.","journal-title":"Mov Disord"},{"issue":"2","key":"636_CR70","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/mds.26377","volume":"31","author":"A Schneeberger","year":"2016","unstructured":"Schneeberger A, Tierney L, Mandler M. Active immunization therapies for Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2016;31(2):214\u201324.","journal-title":"Mov Disord"},{"issue":"2","key":"636_CR71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/mds.26428","volume":"31","author":"E Valera","year":"2016","unstructured":"Valera E, Masliah E. Combination therapies: the next logical step for the treatment of synucleinopathies? Mov Disord. 2016;31(2):225\u201334.","journal-title":"Mov Disord"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-00636-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-00636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-00636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:17:02Z","timestamp":1579893422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-00636-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-00636-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"25 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No violations of ethical standards occurred in the process of preparing this review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article has received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Linda A. Hershey has received honoraria from MedLink Corporation for writing annual reviews on related topics (\u201cMemory Loss\u201d and \u201cSleep and Dementia\u201d). She has received an honorarium from the American College of Physicians for reviewing a paper on a related topic. She sits on the American Academy of Neurology Workgroup that is currently preparing the Mild Cognitive Impairment Quality Measurement Set. She sits on the Oklahoma Longterm Care Stakeholder Committee for the Oklahoma Foundation for Medical Quality. Rhonda Coleman-Jackson declares that she has no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}